Would you consider immunotherapy in high-risk resectable MSI-H colorectal cancer?

Specifically, would you consider either neoadjuvant or adjuvant immunotherapy in this setting, or only after recurrence?

Answer from: Medical Oncologist at Academic Institution

Immunotherapy demonstrated great activity in treating metastatic MSI-H colorectal cancer (CheckMate 142 study, KEYNOTE-177 study, etc). There are now several small studies showing the activity of immunotherapy in early stage or locally advanced colorectal cancer. The NICHE study enrolled 40 pat...

Comments

Medical Oncologist at Eastern Maine Medical Center Cancer Care
Based on this, I plan on having more in-depth disc...

Medical Oncologist at Cancer Center Overlook Hospital
You pointed out the major limitation of the ATOMIC...

Please select the option that best describes you:

Would you consider immunotherapy in high-risk resectable MSI-H colorectal cancer?

Related Questions